Pulse dose glucocorticosteroid therapy in COVID-19 pneumonia patients in an intensive care unit

İlkay Ceylan 1 * , Gürcan Güler 1, Korgün Ökmen 1, Halil Erkan Sayan 1, Ebru Karakoç 2
More Detail
1 Department of Anesthesiology and Reanimation, University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
2 Department of Anesthesiology and Reanimation, Faculty of Medicine in Eskişehir Osmangazi University, Eskişehir, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 19, Issue 3, pp. 55-59. https://doi.org/10.23950/jcmk/12122
OPEN ACCESS 888 Views 582 Downloads
Download Full Text (PDF)

ABSTRACT

Introduction: Coronavirus pneumonia occurs with severe lung tissue damage and rapid activation of cytokines and chemokines, called "cytokine storm," and simultaneously with a high risk of thrombosis and thromboembolism. There is no specific therapy for new coronavirus infection (COVID-19) also for cytokine storm. Therefore it is necessary to search for effective anti-inflammatory treatment. The aim of this study is to investigate the efficacy of pulse-dose glucocorticosteroid use in the treatment of COVID-19 patients hospitalized in the intensive care unit.
Material and methods: The efficacy of pulse dose glucocorticosteroid therapy with 250-1000 mg for three days methylprednisolone 1 mg/kg for 5-7 days more in 144 patients in an intensive care unit with severe coronavirus pneumonia was studied in a retrospective analysis of 55 patients in the standard dose glucocorticosteroid (1 mg/kg/day methylprednisolone) group. The study’s primary endpoint was mortality in ICU, and the secondary endpoint was the effects on inflammatory markers. The treatment groups' disease severities were initially the same.
Results: Pulse dose glucocorticosteroid therapy did not reduce overall intensive care mortality but also increased it. C-reactive protein and fibrinogen levels decreased statistically significantly from the 1st day of admission, but D-dimer did not change statistically significantly. Neutrophilia was seen after steroid use, but it was significantly higher in the pulse dose group. Recovery in the pulse dose group was slower (median ICU stay was 12 days in the pulse dose group versus 10 days in the standard dose group, p=0.002)
Conclusion: Pulse dose glucocorticosteroid therapy has a rapid anti-inflammatory effect but did not reduce intensive care mortality, also increased intensive care length of stay in our cohort.
Keywords: pulse dose glucocorticosteroids, critical care, mortality, thrombosis, D-dimer, COVID-19

CITATION

Ceylan İ, Güler G, Ökmen K, Sayan HE, Karakoç E. Pulse dose glucocorticosteroid therapy in COVID-19 pneumonia patients in an intensive care unit. J CLIN MED KAZ. 2022;19(3):55-9. https://doi.org/10.23950/jcmk/12122

REFERENCES

  • Mehta P, McAuley D, Brown M. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet.2020;395(10229):1033–34. https://doi.org/10.1016/S0140-6736(20)30628-0
  • Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews. 2020;53:38–42. https://doi.org/10.1016/j.cytogfr.2020.04.002
  • Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020;117(20):10970–5. https://doi.org/10.1073/ pnas.2005615117
  • Ministry of Health of the Turkish Republic. General Directorate of Public Health. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) guidelines. Ankara/Turkiye. Version 11/Novemeber/2020
  • Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: The Current evidence and treatment strategies. Front Immunol. 2020;11:1708. https://doi.org/10.3389/fimmu.2020.01708
  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
  • Yang X, Yu Y, Xu J,Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481. https://doi.org/10.1016/S2213-2600(20)30079-5
  • Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. ClinImmunol. 2020;214:108393. https://doi.org/10.1016/j.clim.2020.108393
  • Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP et al. Impact of corti-costeroid therapy on outcomes of persons with SARS-CoV-2, SARS- CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503–11. https://doi.org/10.1038/s41375-020-0848-3
  • Lee N, Allen Chan KC, Hui DS, Ng EKO, Wu A, Chiu RWK, et al. Effects of early corticosteroid treatment on plasma SARS- associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31:304–9. https://doi.org/10.1016/j.jcv.2004.07.006
  • Li S, Hu Z, Song X. High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19. Clinical Infectious Diseases. 2021; 72(7):1297-98. https://doi.org/10.1093/cid/ciaa829
  • Zhao Z. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. Journal of Medical Microbiology. 2003;52(8):715–20. https://doi.org/10.1099/jmm.0.05320-0
  • Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B et al. High–Dose Pulse Versus Non-pulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome. American Journal of Respiratory and Critical Care Medicine. 2003;168(12):1449–56. https://doi.org/10.1164/rccm.200306-766OC
  • Majoor CJ, Sneeboer MMS, de Kievit A, Meijers JCM, van der Poll T, Lutter R, et al. The influence of corticosteroids on hemostasis in healthy subjects. Journal of Thrombosis and Haemostasis. 2016;14(4):716–23. https://doi.org/10.1111/jth.13265
  • Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case- Control Study. JAMA Internal Medicine. 2013;173(9):743. https://doi.org/10.1001/jamainternmed.2013.122
  • Trahtemberg U, Fritzler MJ. COVID-19-associated autoimmunity as a feature of acute respiratory failure. Intensive Care Medicine. 2021;30:1-4. https://doi.org/10.1007/s00134-021-06408-z
  • Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. Journal of Thrombosis and Haemostasis. 2020;18(6):1324–9. https://doi.org/10.1111/jth.14859
  • Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
  • Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How Glucocorticoids Affect the Neutrophil Life. International Journal of Molecular Sciences. 2018;19(12):4090. https://doi.org/10.3390/ijms19124090
  • Kayrak M, Erdoğan Hİ, Solak Y, Akıllı H, Gül EE, Yıldırım O, et al. Prognostic Value of Neutrophil to Lymphocyte Ratio in Patients with Acute Pulmonary Embolism: A Retrospective Study. Heart, Lung and Circulation. 2014;23(1):56–62. https://doi.org/10.1016/j.hlc.2013.06.004
  • Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18. https://doi.org/10.1186/s12967-020-02374-0
  • Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Medical Virology. 2020; [Epub ahead of print]. https://doi.org/10.1002/jmv.25819
  • Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to- lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. 2020;81(1):e6–12. https://doi.org/10.1016/j.jinf.2020.04.002
  • Imtiaz F, Shafique K, Mirza S, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. International Archives of Medicine. 2012;5(1):2. https://doi.org/10.1186/1755-7682-5-2
  • Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomized controlled clinical trial. Eur Respir J. 2020; https://doi.org/10.1183/13993003.02808-2020